Latest Period
Q2 2026
Security Snapshot
TherapeuticsMD, Inc. - Common Stock, par value $0.001 per share (TXMD) Institutional Ownership
CUSIP: 88338N206
13F Institutional Holders and Ownership History from Q4 2021 to Q2 2026
Institutions Reporting
44
Shares (Excl. Options)
3,666,322
Price
$2.21
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock, par value $0.001 per share
- Symbol
- TXMD on Nasdaq
- All holders as of 30 Jun 2026
- Q2 2026
- Total 13F shares
- 3,666,322
- Total 13F value
- $8,101,690
- Portfolio coverage rank
- 0%
- Share change
- -255,039
- Value change
- -$480,563
- Number of holders
- 44
- Shares outstanding
- 11,627,985
- SEC-reported price per share
- $2.11
- Insider filing price
- $2.11
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- TXMD - TherapeuticsMD, Inc. - Common Stock, par value $0.001 per share is tracked under CUSIP 88338N206.
- 44 institutions reported positions in Q2 2026.
- 2 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 47 to 44 between Q1 2026 and Q2 2026.
- SEC-reported value moved from $7,939,211 to $8,101,690.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 44 institutions filings for Q2 2026.
Security key
88338N206
Latest holder period
Q2 2026
13F holders
44
13D/G owners
2
CIK / CUSIP context first
Open Q2 2026 holders
TXMD full holder history
TherapeuticsMD, Inc. SEC filings
TherapeuticsMD, Inc. company facts
TherapeuticsMD, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 88338N206:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
2
Security
TXMD
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Baselake Partners, LP | 6.8% | +32% | $1,668,383 | +$387,231 | 790,703 | +30% | Baselake Partners, LP | 30 Jun 2026 |
| Clearline Capital LP | 5.5% | $705,096 | 635,222 | Clearline Capital LP | 31 Dec 2024 |
As of 30 Jun 2026, 44 institutional investors reported holding 3,666,322 shares of TherapeuticsMD, Inc. - Common Stock, par value $0.001 per share (TXMD). This represents 32% of the company’s total 11,627,985 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
32%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| Rubric Capital Management LP | 10% | 1,192,191 | 0% | 0.02% | $2,634,742 |
| Clearline Capital LP | 5.5% | 635,222 | 0% | 0.09% | $1,403,841 |
| VANGUARD CAPITAL MANAGEMENT LLC | 3% | 353,697 | 0% | 0% | $781,670 |
| Tejara Capital Ltd | 3% | 344,482 | -0.4% | 0.31% | $761,305 |
| ADAR1 Capital Management, LLC | 2.9% | 342,447 | +64% | 0.04% | $756,808 |
| RENAISSANCE TECHNOLOGIES LLC | 1.3% | 146,599 | +0.27% | 0% | $323,984 |
| MORGAN STANLEY | 1.1% | 129,217 | 0% | 0% | $285,569 |
| BlackRock, Inc. | 0.99% | 115,145 | 0% | 0% | $254,470 |
| GEODE CAPITAL MANAGEMENT, LLC | 0.91% | 105,849 | -3.6% | 0% | $233,989 |
| CITADEL ADVISORS LLC | 0.74% | 86,095 | +26% | 0% | $190,270 |
| VANGUARD FIDUCIARY TRUST CO | 0.55% | 63,831 | 0% | 0% | $141,067 |
| STATE STREET CORP | 0.26% | 30,100 | 0% | 0% | $66,521 |
| XTX Topco Ltd | 0.18% | 21,246 | -23% | 0% | $46,954 |
| DIMENSIONAL FUND ADVISORS LP | 0.17% | 19,719 | +84% | 0% | $43,579 |
| NORTHERN TRUST CORP | 0.16% | 18,556 | +15% | 0% | $41,009 |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 0.15% | 17,000 | 0% | 0% | $37,570 |
| OSAIC HOLDINGS, INC. | 0.13% | 15,198 | +9833% | 0% | $33,586 |
| HRT FINANCIAL LP | 0.13% | 14,727 | 0% | $32,000 | |
| Vanguard Global Advisers, LLC | 0.04% | 4,937 | 0% | 0% | $10,911 |
| UBS Group AG | 0.04% | 4,660 | +1308% | 0% | $10,299 |
| Tower Research Capital LLC (TRC) | 0.01% | 1,582 | +4.8% | 0% | $3,496 |
| SBI Securities Co., Ltd. | 0.01% | 1,263 | +373% | 0% | $2,791 |
| ROYAL BANK OF CANADA | 0.01% | 643 | 0% | $1,000 | |
| Smartleaf Asset Management LLC | 0.01% | 601 | 0% | 0% | $1,346 |
| JPMORGAN CHASE & CO | 0% | 293 | 0% | 0% | $657 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
19
Latest
Q2 2026
Rows shown
1-19 of 19
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q2 | 3,666,322 | $8,101,690 | -$480,563 | $2.21 | 44 |
| 2026 Q1 | 3,930,452 | $7,939,211 | +$1,050,571 | $2.02 | 47 |
| 2025 Q4 | 3,384,889 | $5,517,397 | +$146,413 | $1.63 | 41 |
| 2025 Q3 | 3,303,788 | $3,542,705 | +$51,253 | $1.08 | 43 |
| 2025 Q2 | 3,255,627 | $3,776,528 | -$96,760 | $1.16 | 39 |
| 2025 Q1 | 3,343,589 | $3,092,849 | -$161,728 | $0.92 | 39 |
| 2024 Q4 | 3,528,745 | $3,034,778 | +$127,744 | $0.86 | 38 |
| 2024 Q3 | 3,379,026 | $5,609,223 | -$32,659 | $1.66 | 34 |
| 2024 Q2 | 3,408,566 | $5,487,879 | -$167 | $1.61 | 34 |
| 2024 Q1 | 3,377,053 | $7,732,812 | +$286,534 | $2.29 | 43 |
| 2023 Q4 | 3,251,877 | $7,316,577 | -$358,133 | $2.25 | 36 |
| 2023 Q3 | 2,987,555 | $9,324,433 | +$112,168 | $3.02 | 36 |
| 2023 Q2 | 3,031,054 | $12,488,021 | -$296,992 | $4.12 | 40 |
| 2023 Q1 | 3,115,140 | $11,682,289 | -$1,635,363 | $3.75 | 38 |
| 2022 Q4 | 3,475,915 | $19,431,091 | +$6,039,029 | $5.59 | 43 |
| 2022 Q3 | 2,070,807 | $13,750,198 | -$489,469 | $6.64 | 29 |
| 2022 Q2 | 1,993,507 | $19,835,726 | +$19,831,622 | $9.95 | 36 |
| 2022 Q1 | 10,800 | $4,104 | +$304 | $0.38 | 2 |
| 2021 Q4 | 10,000 | $3,555 | $0.36 | 1 |